Reckitt Benckiser Group plc (RBGPF)
NEUTRALFundamental
52
Precio
$5150.00
Capitalización Bursátil
$32.48B
Parte 1 · Cuánto vale la empresa
Resumen
Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.
Cómo genera ingresos
Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.
Ventaja competitiva
Marca · EstrechaReckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.
Qué impulsa la demanda
DefensivoMost of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.
Los argumentos a favor
Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.
Los argumentos en contra
Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$13.35B
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Beneficio Neto
$2.81B
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Flujo de Caja Libre
$3.09B
Patrimonio Neto Total
$5.67B
Pasivo Total
$10.25B
Ratio de Liquidez
0.59
Cobertura de Intereses
-
Deuda/EBITDA
2.86
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$2156.36
Precio Actual
$5150.00
Margen de Seguridad
-138.8%
Rango de Valor Justo
$1401.63 - $2911.08
Métodos de Estimación
Métricas de Valoración
Ratio P/E
1169.99
ROE
48.0%
Ratio P/B
580.17
P/FCF
1049.76
Margen Bruto
59.6%
ROIC
12.3%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
12.3%
WACC
8.5%
ROIC − WACC
+3.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Criterios de Análisis Fundamental
Superado (10)
- ROIC 12.3%
- Gross Margin 59.6%
- Debt/Equity ratio
- Operating Margin 28.5%
- Positive Free Cash Flow
- Debt/EBITDA
- ROE 42.9%
- Analyst Consensus 76% Buy
- PEG Ratio 0.47
- Net Margin Trend 22.4% vs 10.1%
Fallido (11)
- Price CAGR -3.27%
- P/FCF 1049.76
- P/B Ratio 580.17
- CapEx intensity
- Current Ratio
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 0.3%
- Earnings Surprise avg 2.4%
- Earnings Quality (OCF/NI) 0.66
- Piotroski F-Score 1/9
No disponible (6)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Moderada: cierta brecha entre beneficios y efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Kristoffer Loe Licht | CEO & Executive Director | 49 |
| Ms. Shannon Sue Eisenhardt | CFO & Executive Director | 51 |
| Mr. Nicholas James Ashworth C.F.A. | Senior Vice President of Investor Relations | - |
| Ms. Catheryn O'Rourke | Senior VP, General Counsel & Company Secretary | 52 |
| Ms. Sheila Redzepi | Chief Communications & Corporate Affairs Officer | 46 |
| Mr. Ranjay Radhakrishnan | Chief Human Resources Officer | 54 |
| Mr. Jerome Lemaire | President North America | 51 |
| Ms. Angela Naef Ph.D. | Chief Research & Development Officer | 49 |
| Ms. Susan Sholtis | President of Nutrition | 58 |
| Dr. Alessio Fasano M.D. | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | - |
Riesgo de Auditoría
4
Riesgo del Consejo
2
Riesgo de Compensación
3
Riesgo de Derechos del Accionista
1
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for RBGPF, sourced from Markets Gazette.